Gattex / Revestive (GLP-2 analog)
The Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. None of the compounds covered are approved for the uses described here by the U.S. FDA, Australia's Therapeutic Goods Administration (TGA), New Zealand's Medsafe, or the equivalent regulator in most other countries.
Most are sold for laboratory research only, a few are prescription-only drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful wherever you live. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
Cross-checked against 50–100 independent sources per claim — the house standard. How this reference is checked
A DPP-4-resistant GLP-2 analog that is FDA-approved (2012) for short bowel syndrome, making it one of the few genuinely approved compounds in the healing category. It increases intestinal villus height and crypt depth to expand absorptive surface area, and this mechanism is well characterized in registrational trials. Its approved use is a narrow clinical indication, however – the broader "gut mucosal healing and regeneration" framing used by research-peptide sellers goes well beyond the tested population, and it carries a known theoretical risk of promoting intestinal polyp/neoplastic growth.
The full published spec sheet — dose units, timing, frequency, and cycle length — is included with membership.
The published dose for this compound, shown as reference. Included with membership.
